A Phase 1, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Doses of CBT101 given intranasally in Healthy Male Subjects.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515549-40-00

Acronym

CBT101/OP112923.CER

Enrollment

Registered

2025-01-21

Start date

2025-02-21

Completion date

2025-09-26

Last updated

2025-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurological disease

None listed

Sex/Gender

Male

Age

18 Years to 64 Years

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026